Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

Zhao C, Sham HL, Sun M, Stoll VS, Stewart KD, Lin S, Mo H, Vasavanonda S, Saldivar A, Park C, McDonald EJ, Marsh KC, Klein LL, Kempf DJ, Norbeck DW.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5499-503. Epub 2005 Oct 3.

PMID:
16203141
2.

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.

Sham HL, Betebenner DA, Rosenbrook W, Herrin T, Saldivar A, Vasavanonda S, Plattner JJ, Norbeck DW.

Bioorg Med Chem Lett. 2004 May 17;14(10):2643-5.

PMID:
15109669
3.

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

Chen X, Kempf DJ, Li L, Sham HL, Vasavanonda S, Wideburg NE, Saldivar A, Marsh KC, McDonald E, Norbeck DW.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3657-60.

PMID:
14552751
4.

Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.

Sham HL, Zhao C, Li L, Betebenner DA, Saldivar A, Vasavanonda S, Kempf DJ, Plattner JJ, Norbeck DW.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3101-3.

PMID:
12372511
5.

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.

Stoll V, Qin W, Stewart KD, Jakob C, Park C, Walter K, Simmer RL, Helfrich R, Bussiere D, Kao J, Kempf D, Sham HL, Norbeck DW.

Bioorg Med Chem. 2002 Aug;10(8):2803-6.

PMID:
12057670
6.

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).

Sham HL, Betebenner DA, Chen X, Saldivar A, Vasavanonda S, Kempf DJ, Plattner JJ, Norbeck DW.

Bioorg Med Chem Lett. 2002 Apr 22;12(8):1185-7.

PMID:
11934584
7.

Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.

Kati WM, Montgomery D, Maring C, Stoll VS, Giranda V, Chen X, Laver WG, Kohlbrenner W, Norbeck DW.

Antimicrob Agents Chemother. 2001 Sep;45(9):2563-70.

8.

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

Sham HL, Betebenner DA, Herrin T, Kumar G, Saldivar A, Vasavanonda S, Molla A, Kempf DJ, Plattner JJ, Norbeck DW.

Bioorg Med Chem Lett. 2001 Jun 4;11(11):1351-3. Erratum in: Bioorg Med Chem Lett. 2004 May 17;14(10):2695.

PMID:
11378352
9.

Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides.

Kati WM, Sham HL, McCall JO, Montgomery DA, Wang GT, Rosenbrook W, Miesbauer L, Buko A, Norbeck DW.

Arch Biochem Biophys. 1999 Feb 15;362(2):363-75.

PMID:
9989947
10.

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.

Chen X, Kempf DJ, Sham HL, Green BE, Molla A, Korneyeva M, Vasavanonda S, Wideburg NE, Saldivar A, Marsh KC, McDonald E, Norbeck DW.

Bioorg Med Chem Lett. 1998 Dec 15;8(24):3531-6.

PMID:
9934466
11.

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.

Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ, Norbeck DW.

Antimicrob Agents Chemother. 1998 Dec;42(12):3218-24.

12.

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski B, Denissen JF, Kohlbrenner W, Plattner JJ, Leonard JM, Norbeck DW, Kempf DJ.

Virology. 1998 Oct 25;250(2):255-62.

13.

In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A.

J Virol. 1998 Sep;72(9):7532-41.

14.

Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.

Eastman PS, Mittler J, Kelso R, Gee C, Boyer E, Kolberg J, Urdea M, Leonard JM, Norbeck DW, Mo H, Markowitz M.

J Virol. 1998 Jun;72(6):5154-64.

15.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

Kempf DJ, Sham HL, Marsh KC, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, Kati WM, Ruiz L, Zhao C, Fino L, Patterson J, Molla A, Plattner JJ, Norbeck DW.

J Med Chem. 1998 Feb 12;41(4):602-17.

PMID:
9484509
16.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM.

Antimicrob Agents Chemother. 1997 Mar;41(3):654-60.

17.

Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.

Sham HL, Zhao C, Marsh KC, Betebenner DA, Lin S, Rosenbrook W Jr, Herrin T, Li L, Madigan D, Vasavanonda S, Molla A, Saldivar A, McDonald E, Wideburg NE, Kempf D, Norbeck DW, Plattner JJ.

Biochem Biophys Res Commun. 1996 Aug 14;225(2):436-40.

PMID:
8753780
18.

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ.

Nat Med. 1996 Jul;2(7):760-6.

PMID:
8673921
19.

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.

Bilello JA, Bilello PA, Stellrecht K, Leonard J, Norbeck DW, Kempf DJ, Robins T, Drusano GL.

Antimicrob Agents Chemother. 1996 Jun;40(6):1491-7.

20.

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

Sham HL, Zhao C, Stewart KD, Betebenner DA, Lin S, Park CH, Kong XP, Rosenbrook W Jr, Herrin T, Madigan D, Vasavanonda S, Lyons N, Molla A, Saldivar A, Marsh KC, McDonald E, Wideburg NE, Denissen JF, Robins T, Kempf DJ, Plattner JJ, Norbeck DW.

J Med Chem. 1996 Jan 19;39(2):392-7.

PMID:
8558507
21.

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD.

J Virol. 1995 Feb;69(2):701-6.

22.

Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.

Kaplan AH, Krogstad P, Kempf DJ, Norbeck DW, Swanstrom R.

Antimicrob Agents Chemother. 1994 Dec;38(12):2929-33.

23.

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW, Swanstrom R.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5597-601.

24.

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.

Kageyama S, Hoekzema DT, Murakawa Y, Kojima E, Shirasaka T, Kempf DJ, Norbeck DW, Erickson J, Mitsuya H.

AIDS Res Hum Retroviruses. 1994 Jun;10(6):735-43.

PMID:
8074936
25.
26.

In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.

Kageyama S, Weinstein JN, Shirasaka T, Kempf DJ, Norbeck DW, Plattner JJ, Erickson J, Mitsuya H.

Antimicrob Agents Chemother. 1992 May;36(5):926-33.

27.

Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture.

Hung LF, Brumbaugh AE, Bhatia G, Marion PL, Hung PP, Norbeck DW, Plattner JJ, Robinson WS.

J Med Virol. 1991 Nov;35(3):180-6.

PMID:
1804929
28.

Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Kempf DJ, Marsh KC, Paul DA, Knigge MF, Norbeck DW, Kohlbrenner WE, Codacovi L, Vasavanonda S, Bryant P, Wang XC, et al.

Antimicrob Agents Chemother. 1991 Nov;35(11):2209-14.

29.

Potent HIV-1 protease inhibitors with antiviral activities in vitro.

Sham HL, Betebenner DA, Wideburg NE, Saldivar AC, Kohlbrenner WE, Vasavanonda S, Kempf DJ, Norbeck DW, Zhao C, Clement JJ, et al.

Biochem Biophys Res Commun. 1991 Mar 29;175(3):914-9.

PMID:
2025263
30.

Efficiency of phosphorylation of the cyclobut-G (A-69992) enantiomers by HSV-1 thymidine kinase does not correlate with their anti-herpesvirus activity.

Kohlbrenner WE, Carter CD, Fesik SW, Norbeck DW, Erickson J.

Biochem Pharmacol. 1990 Dec 1;40(11):R5-10. No abstract available.

PMID:
2176497
31.

Structure-based, C2 symmetric inhibitors of HIV protease.

Kempf DJ, Norbeck DW, Codacovi L, Wang XC, Kohlbrenner WE, Wideburg NE, Paul DA, Knigge MF, Vasavanonda S, Craig-Kennard A, et al.

J Med Chem. 1990 Oct;33(10):2687-9. No abstract available.

PMID:
2213822
32.

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW, Plattner JJ, Rittenhouse JW, Turon M, Wideburg N, et al.

Science. 1990 Aug 3;249(4968):527-33.

PMID:
2200122
33.

Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS.

Norbeck DW, Kern E, Hayashi S, Rosenbrook W, Sham H, Herrin T, Plattner JJ, Erickson J, Clement J, Swanson R, et al.

J Med Chem. 1990 May;33(5):1281-5. No abstract available.

PMID:
2329551
34.

Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro.

Hayashi S, Norbeck DW, Rosenbrook W, Fine RL, Matsukura M, Plattner JJ, Broder S, Mitsuya H.

Antimicrob Agents Chemother. 1990 Feb;34(2):287-94.

35.

A novel prodrug of an impermeant inhibitor of 3-deoxy-D-manno-2-octulosonate cytidylyltransferase has antibacterial activity.

Norbeck DW, Rosenbrook W, Kramer JB, Grampovnik DJ, Lartey PA.

J Med Chem. 1989 Mar;32(3):625-9.

PMID:
2537425

Supplemental Content

Loading ...
Support Center